急性単純性膀胱炎に対するCefpodoxime proxetilの有効性と安全性の検討

Abstract

1) 1群82例(CPDX-PR 200mg/day, 分二, 3日間投与)のUTI薬効評価基準による総合臨床効果は, 著効64例, 有効17例, 無効1例で有効率98.8%であった。2) 2群の35例(CPDX-PR 200mg/day, 分二, 4～7日間投与投与)の総合臨床効果は, 著効18例, 有効15例, 無効2例で有効率94.3%であった。3) 150例中1例に一過性の軽度の副作用がみられ, 安全性は99.3%であった。4)起炎菌は, グラム陰性桿菌127株(84.7%), グラム陽性球菌21株(14.0%), 真菌2株(1.3%)で, E. coliは105株(70.0%)を占めた。5) E. coliに対する抗菌力は, 開発当初と同程度で, CFIX, CFTM-PIのそれとも同程度であった

One hundred and fifty female patients with acute uncomplicated cystitis were given 200 mg of CPDX-PR twice daily for 3-7 days to evaluate both its overall clinical efficacy and its adverse effects. In 82 cases (Group I) in which it was administered for 3 days, the overall clinical efficacy, evaluated by the criteria proposed by the Japanese UTI committee, was excellent in 64 cases, moderate in 17 and poor in one, with the effective rate being 98.8%. In 35 cases (Group II) in which it was administered for 4-7 days, the overall clinical efficacy was excellent in 18 cases, moderate in 15 and poor in 2, with the effective rate being 94.3%. The overall clinical evaluation was not performed in another 33 cases because they were given CPDX-PR for more than 8 days or 300 mg/day. Subjective adverse effects such as hoarseness and lingual inflammation were observed in only one of the 150 cases, but they disappeared spontaneously after the cessation of administration of CPDX-PR. These findings suggest that CPDX-PR is one of the most effective and safe antibiotic in the treatment of acute uncomplicated cystitis.